Skip to main content
Back
Watch Compare

Outlook Therapeutics, Inc.

Data quality: 100%
OTLK
Nasdaq Manufacturing Chemicals
$0.22
▼ $0.03 (-10.52%)
Mkt Cap: 23.41 M
Price
$0.22
Mkt Cap
23.41 M
Day Range
$0.21 — $0.25
52-Week Range
$0.16 — $3.39
Volume
4,486,174
Open $0.25
50D / 200D Avg
$0.38
41.70% below
50D / 200D Avg
$1.27
82.34% below

Quick Summary

Key Takeaways

Negative free cash flow of -55.80 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROICN/A
Net Margin-7276.84%
Op. Margin-4169.60%

Safety

Debt / Equity
N/A
Current Ratio0.35
Interest Coverage-177.52

Valuation

PE (TTM)
-0.23
Above sector avg (-1.48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -0.2 -1.5
P/B — 1.6
ROE % — -53.4
Net Margin % -7276.8 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.41 M Net Income (TTM) -102.86 M
ROE N/A ROA -506.33%
Gross Margin -83.50% Operating Margin -4169.60%
Net Margin -7276.84% Free Cash Flow (TTM) -55.80 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.35
Interest Coverage -177.52 Asset Turnover 0.07
Working Capital -31.89 M Tangible Book Value -38.55 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.23 Forward P/E N/A
P/B Ratio N/A P/S Ratio 16.56
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -238.34%
Market Cap 23.41 M Enterprise Value 14.74 M
Per Share
EPS (Diluted TTM) -2.89 Revenue / Share 0.01
FCF / Share -0.53 OCF / Share -0.53
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 54.25%
SBC-Adj. FCF -63.76 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.41 M — — — —
Net Income -62.42 M -75.37 M -58.98 M -66.05 M -53.16 M
EPS (Diluted) -1.79 -4.06 -0.24 -0.31 -0.35
Gross Profit 57,205.0 — — — —
Operating Income -67.06 M -71.70 M -53.13 M -63.07 M -51.73 M
EBITDA — — — — —
R&D Expenses 27.18 M 41.76 M 26.45 M 42.33 M 38.96 M
SG&A Expenses 39.94 M — — — —
D&A 117,052.0 113,859.0 44,188.0 204,694.0 262,140.0
Interest Expense -283,128.0 3.16 M -1.56 M -1.49 M -936,127.0
Income Tax -1.55 M 2,800.0 2,800.0 2,800.0 2,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 18.58 M 28.82 M 32.30 M 28.53 M 22.81 M
Total Liabilities 50.77 M 101.90 M 46.74 M 19.79 M 18.20 M
Shareholders' Equity -32.19 M -73.08 M -14.44 M 8.74 M 4.61 M
Total Debt — — — — —
Cash & Equivalents 8.08 M 14.93 M 23.39 M 17.40 M 14.48 M
Current Assets 17.39 M 27.42 M 30.98 M 27.52 M 21.51 M
Current Liabilities 45.81 M 42.55 M 46.73 M 19.73 M 6.75 M